Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q2 EPS of ($1.07), $0.25 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.